Skip to content
Open access · OA via Europe PMC

Spermidine in Alzheimer's Disease: Evidence from Animal Models and Human Studies.

Angelucci F, Cerman J, Amlerova J, Sheardova K, Pavlik J, Hort J.

Degenerative neurological and neuromuscular disease · 2026 · ▲ 3 citations

Abstract

Spermidine is a naturally occurring polyamine involved in multiple cellular processes, including growth regulation, protein translation, and autophagy(definition). Increasing attention has been devoted to its potential neuroprotective effects, particularly in Alzheimer's disease (AD), a neurodegenerative disorder characterized by β-amyloid and phosphorylated tau accumulation, synaptic dysfunction, and progressive neuronal loss. In this narrative review, we examine potential mechanisms through which spermidine may influence AD pathophysiology and summarize available preclinical and clinical evidence. Preclinical studies indicate that spermidine induces autophagy, a key cellular clearance pathway responsible for removing damaged organelles and aggregated proteins. Because impaired neuronal autophagy contributes to the accumulation of β-amyloid and tau in AD, increasing intracellular spermidine levels may enhance the degradation of these toxic species. In addition, spermidine exhibits anti-inflammatory and antioxidant properties, attenuates microglial activation, and supports mitochondrial function. In animal models of AD and brain aging, spermidine administration has been associated with improvements in cognitive performance and synaptic function. However, human clinical evidence remains limited and largely inconclusive. Observational studies suggest associations between higher dietary spermidine intake and better cognitive outcomes, but do not establish causality. Randomized clinical trials to date are few, include small and heterogeneous populations, and have not demonstrated consistent effects on primary cognitive endpoints. Overall, spermidine represents a biologically plausible modulator of pathways relevant to neurodegeneration, but translation of preclinical findings into clinical benefit remains uncertain. Current evidence is insufficient to support its use as a therapeutic or preventive intervention in AD, and further well-designed clinical studies are required to clarify its efficacy and mechanisms of action.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.2147/dnnd.s608341
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
F, A., J, C., J, A., K, S., J, P., &amp; J., H. (2026). Spermidine in Alzheimer's Disease: Evidence from Animal Models and Human Studies. <em>Degenerative neurological and neuromuscular disease</em>. https://doi.org/10.2147/dnnd.s608341
Vancouver
F A, J C, J A, K S, J P, J. H. Spermidine in Alzheimer's Disease: Evidence from Animal Models and Human Studies. Degenerative neurological and neuromuscular disease. 2026. doi:10.2147/dnnd.s608341.
BibTeX
@article{angelucci2026Spermi, title = {Spermidine in Alzheimer's Disease: Evidence from Animal Models and Human Studies.}, author = {Angelucci F and Cerman J and Amlerova J and Sheardova K and Pavlik J and Hort J.}, journal = {Degenerative neurological and neuromuscular disease}, year = {2026}, doi = {10.2147/dnnd.s608341}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings